Sabin monovalent oral polio vaccines: Review of past experiences and their potential use after polio eradication

Clinical Infectious Diseases

Volumn 33, Issue 4, 2001, Pages 531-541

  Caceres V M ^a   Sutter, R W ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

DRUG SAFETY; ERADICATION THERAPY; IMMUNE DEFICIENCY; IMMUNOGENICITY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VIRUS REPLICATION;

ANTIBODIES, VIRAL; CHILD; DRUG STABILITY; HISTORY, 20TH CENTURY; HUMANS; IMMUNIZATION SCHEDULE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 0035882190     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321905     Document Type: Review

References (68)

1. Progress toward global poliomyelitis eradication: 1999
2. Invited commentary: The scientific basis for stopping polio immunization
3. Transmissibility and persistence of oral polio vaccine viruses: Implications for the global eradication initiative
4. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
5. Stopping poliovirus vaccination after eradication: Issues and challenges
6. Oral immunization against poliomyelitis
7. Problems associated with the use of live poliovirus vaccine
8. Live attenuated poliovirus vaccines
9. Properties and behaviour of orally administered poliovirus vaccine
10. Status of vaccination against poliomyelitis with particular reference to oral vaccination
11. On the role of the World Health Organization in the development of Sabin vaccines
12. Oral poliovirus vaccine: History of its development and prospects for eradication of poliomyelitis
13. Intratypic serodifferentiation tests on polio type 1 virus strains isolated before and after vaccination with attenuated Sabin type 1 polio vaccine
14. Antibody response to type 1 oral polio vaccine
15. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries
16. Part 2. Virological and immunological characteristics of vaccinal infection in children inoculated per os with a live poliomyelitis vaccine made for the Sabin strains
17. 2O)
18. 2-stabilized oral poliovaccine
19. Development of a more thermostable poliovirus vaccine
20. Experimental study of immunization of young children in Moscow with live poliovirus vaccine from Sabin strains incorporated in dragée-candy
21. Variations in the responses of infants to live attenuated poliovirus vaccines
22. Immunization with live attenuated poliovirus vaccine
23. The response of newborn infants to vaccination with living type 1 poliovirus (Sabin-LSc, 2ab): Preliminary report
24. Preliminary report on the susceptibility of newborn infants to infection with poliovirus strains in an attenuated virus vaccine
25. Monovalent neonatal polio immunization: A strategy for the developing world
26. Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants
27. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains
28. Report on oral polio vaccines
29. New data on live vaccines against poliomyelitis, mumps and measles
30. Part 2. Virological and immunological characteristics of vaccinal infection in children inoculated per os with a live poliomyelitis vaccine made from the Sabin strains
31. Mass oral (Sabin) poliomyelitis vaccination: Virological and serological surveillance in Czechoslovakia, 1958-59 and 1960
32. Comparative serological studies on the effectiveness of monovalent live poliovirus vaccines given alternatively in the order 2-3-1 and 1-3-2
33. Behavior of Sabin type 1 attenuated poliovirus in an infant population infected with ECHO 14 virus
34. Part 1. Recent studies and field test with a live attenuated poliovirus vaccine
35. Factors affecting the efficacy of live poliovirus vaccine in warm climates
36. Oral poliovirus vaccination in children: A study suggesting enterovirus interference
37. 5. Poliomyelitis infection rate among Mexican children fed attenuated poliovirus vaccines
38. Large-scale use of Sabin type 2 attenuated polio vaccine in Singapore during a type 1 poliomyelitis epidemic
39. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982
40. Status of field trials with an orally administered, live attenuated poliovirus vaccine
41. The effect of diarrhea on oral poliovirus vaccine failure in Brazil
42. Effect of diarrhea on the humoral response to oral polio vaccination
43. The use of the Sabin vaccine, of live poliomyelitis virus, in Mexico: Results of a large scale study (sp)
44. Excretion of virus after ingestion of large doses of type 1 or of mixture of all three types, in relation to level of placentally transmitted antibody
45. Evidence on the safety and efficacy of live poliomyelitis currently in use, with special reference to type 3 poliovirus
46. Paralytic disease associated with oral polio vaccines
47. Vaccine-associated poliomyelitis in the United States 1961-1972
48. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease
49. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91
50. Stopping a polio outbreak in the post-eradication era
51. Preliminary report on mass oral immunization of population against poliomyelitis with live virus vaccine from A. B. Sabin's attenuated strains
52. Serologic evaluation of various schedules of oral immunization
53. Immunization in India with trivalent and monovalent oral poliovirus vaccines of enhanced potency
54. Studies on the use of oral live poliovirus vaccine
55. Randomised trial of alternative formulations of oral poliovaccine in Brazil
56. Use of Sabin's live poliovirus vaccine in Mexico; results of a large-scale trial
57. Field trial with Sabin's live poliovirus vaccine in Czechoslovakia, 1958-59
58. A small-scale trial on vaccination and revaccination with live attenuated polioviruses in the Netherlands
59. The antibody response in children vaccinated with a) the live attenuated polioviruses and b) the fourth dose of inactivated polio vaccine